Protein arginine methyltransferases (PRMT) catalyze protein arginine methylation and play an important role in many biological processes. Aberrant PRMT expression in tumor cells has been documented in several common cancer types; however, its precise contribution to hepatocellular carcinoma (HCC) cell invasion and metastasis is not fully understood. In this study, we identified a new oncogene, PRMT9, whose overexpression strongly promotes HCC invasion and metastasis. PRMT9 expression was detected more frequently in HCC tissues than in adjacent noncancerous tissues. Thus, PRMT9 may serve as a candidate prognostic biomarker and a potential therapeutic target.
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| INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide. 1 Curative surgical resection is the most common treatment for HCC, but the 5-year postoperative survival rate is unsatisfactory. This poor prognosis is mainly due to the high frequency of tumor recurrence and distant metastasis after curative surgical resection. 2 Therefore, a better understanding of the molecular mechanisms underlying HCC metastasis will help prevent HCC recurrence and metastasis.
Epithelial-mesenchymal transition (EMT) is known to be involved in cancer metastasis and is a process in which epithelial cancer cells lose their typical epithelial characteristics and acquire mesenchymal traits. 3 During EMT, proteins involved in cell junctions such as E-cadherin and ZO-1 are downregulated, while mesenchymal markers such as Fibronectin and vimentin are upregulated. 4 This conversion is believed to be triggered by multiple zinc finger proteins, including Snail, Slug, ZEB1, ZEB2 and Twist. [5] [6] [7] As the regulators of EMT, zinc finger proteins directly promote the repression of E-cadherin at the transcriptional level by binding to E-box motifs, resulting in a loss of cell adhesion, which allows cells to migrate and metastasize. 8 A large number of studies show that EMT are regulated by numerous signaling pathways, including phosphoinositide 3-kinase (PI3K)/Akt-, Hedgehog-, Notch-, Wnt-and nuclear factor-jB (NF-jB)-dependent pathways. 9 Cancer cells undergoing EMT become mobile and invasive, enabling metastasis and chemotherapy resistance. 10 Recently, it was
shown that HCC cells undergoing EMT play a vital role in the dissemination of malignant hepatocytes and, thus, influence HCC recurrence and prognosis. 11, 12 Therefore, identifying the underlying molecular mechanism during HCC progression may ultimately provide innovative therapeutic strategies against HCC.
Protein arginine methylation is a widespread posttranslational modification that impacts numerous cellular processes, including transcription, RNA splicing, DNA repair, cell signaling and cell fate decisions. 13, 14 This posttranslational modification is catalyzed by the 9 protein arginine methyltransferases (PRMT). 14 According to their catalytic activity, PRMT are categorized into 3 groups. Type I enzymes, including PRMT1, PRMT2, PRMT3, PRMT4, PRMT6 and PRMT8, catalyze the synthesis of monomethylarginine (MMA) and asymmetric dimethylarginine (aDMA), whereas type II enzymes (PRMT5 and PRMT9) carry out the formation of MMA and sDMA. 14, 15 PRMT7 is the only type III enzyme, and it catalyzes the formation of MMA. 16 Numerous studies have shown that the aberrant expression PRMT is associated with cancer. These dysregulated proteins can impact multiple pathways that contribute to tumorigenesis, including the proliferation, cell cycle, apoptosis, and invasion and metastatic capacity of tumor cells. 14, 17 Several studies have
shown that PRMT1 and PRMT5 are overexpressed in HCC, and their high expression indicates a poor prognosis in HCC patients. 18, 19 This evidence implies that PRMT may play a crucial role in HCC progression. However, the roles of PRMT, especially PRMT9, in the regulation of HCC invasion and metastasis have not been fully elucidated.
In this study, we identified that PRMT9 has an important role in HCC invasion and in the EMT process of HCC cells. Further investigation showed that PRMT9 was upregulated in HCC tissues and cell lines. Table S1 .
| Plasmids and stable overexpression and knockdown of PRMT9 in hepatocellular carcinoma cells
The pLV-Puro-GFP-PRMT9 lentiviral vector was purchased from Guangzhou Cyagen Biosciences. The GV248-GFP-shRNA-PRMT9 lentiviral vectors containing shRNA targeting PRMT9 were purchased from Shanghai GeneChem and the hairpin shRNA sequences are described in Document S1. The lentiviruses produced from pLV-Puro-GFP-PRMT9 lentiviral vectors were used to infect Huh7 and Bel7402 cells, and the shRNA-PRMT9 lentiviruses were used to infect SK-Hep1 cells. Cells infected with pLV-Puro-GFP or PGCSIL-GFP were used as controls.
Infected cells were selected with 2 lg/mL puromycin for 2 weeks.
| Wound healing assay
Cells were grown to 100% confluence in 6-well plates. The confluent cell monolayer was scratched with a 200-lL sterile plastic pipette tip to produce an artificial wound. Cell debris was removed by washing with PBS, and cells were cultured in fresh medium without FBS for 48 hours.
Then, the rate of wound closure was examined and photographed.
| Cell migration and invasion assay
Cell migration and invasion ability were measured using Corning 
| In vivo metastasis assays
BALB/C nude mice (5 weeks old) were bred under standard conditions and maintained according to the institutional guidelines for animal care.
All animal research procedures were approved by the Animal Care and Use Ethics Committee, Sun Yat-Sen University. For the in vivo lung metastasis assay, Bel7402-control and Bel7402-PRMT9 (2 9 10 6 in 25 lL PBS) cells were injected orthotopically into the left liver lobe of BALB/C nude mice (10 in each group). Six weeks later, the mice were killed, and the lung tissues were harvested. Liver and lung tissues were paraffin-embedded and stained with H&E for histological validation. and SYBR Green Master Mix (Takara Bio, Otsu, Japan). The primer sequences used in this study are listed in Document S1.
| Western blot analysis
Western blotting was performed in accordance with the standard methods. Briefly, cells were lysed in RIPA buffer containing protease inhibitor cocktail (FDbio Science, Shanghai, China). Protein extracts were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA). After blocking with 5% non-fat dry milk, the membranes were incubated with primary antibody at 4°C overnight, followed by an incubation with HRP-conjugated secondary antibody for 1 hours at room temperature. Immunoreactive bands were detected by enhanced chemiluminescence (ECL; Millipore, Billerica, MA, USA). The primary antibodies and dilutions used for western blot analysis are listed in Table S1 .
| Immunofluorescence assay
Cells were fixed with 4% paraformaldehyde for 15 minutes at 4°C on glass coverslips and permeabilized with 0.1% Triton-X 100 for Zeiss GmbH, Oberkochen, Germany). The primary antibodies and dilutions used for immunofluorescence assays are listed in Table S1 .
| Statistical analysis
Statistical analyses were performed using SPSS 17.0 software. Data are expressed as the means AE SD of 3 independent experiments.
Quantitative data between groups were compared using Student's t immunohistochemical staining is shown in Figure 1A3 . Among the HCC specimens, 12 pairs (60%) had higher PRMT9 expression levels in the portal vein tumor thrombosis samples than in the primary HCC tissues ( Figure 1A3 ).
PRMT9 expression levels were compared between the noncancerous LO2 liver cell line and the 4 HCC cell lines. Western blot assays showed that PRMT9 expression was increased in highly metastatic HCC cell lines (SK-Hep1 and MHCC97H; Figure 1B ).
Upregulation of PRMT9 was significantly associated with hepatitis B virus antigen (HBsAg, P = .011), vascular invasion (P = .02), tumor differentiation (P = .02) and TNM stage (P = .016; Table 1 ). KaplanMeier analysis showed that HCC patients with positive PRMT9 staining had shorter overall survival times than those with negative PRMT9 expression ( Figure 1C ). Cox's multivariate proportional hazards model indicated that PRMT9-positive staining was an independent predictor of survival in HCC patients after curative resection (Table 2) . Taken together, these observations indicated that the overexpression of PRMT9 may contribute to HCC metastasis.
| PRMT9 promotes hepatocellular carcinoma cell migration and tumor metastasis
Because our clinicopathological correlation analysis indicated that PRMT9 upregulation was significantly associated with vascular invasion, we further investigated the role of PRMT9 in HCC cell migration and invasion. Two stable cell lines, Huh7-PRMT9 and Bel7402-PRMT9, were established for this purpose. Wound healing assays showed that the upregulation of PRMT9 expression significantly increased the capacity of Huh7 and Bel7402 cells to close the scratched "wound" (Figure 2A ,B and Figure S1A ,B). Transwell assays further revealed that the upregulation of PRMT9 enhanced the migration and invasion of Huh7 and Bel7402 cells (Figure 2C,D) . In contrast, when PRMT9 was silenced by targeted shRNA, cell migration and invasion were significantly inhibited ( Figure 2E ,F and Figure S1C ).
To further evaluate the effect of PRMT9 on tumor metastasis in vivo, cells were injected into the livers of nude mice. The PRMT9-expressing group showed an increased incidence of lung metastasis compared with that of the control group ( Figure 2G ). These data indicated that PRMT9 had an important role in promoting HCC invasion and metastasis.
| PRMT9 induces epithelial-mesenchymal transition in hepatocellular carcinoma
As PRMT9 was involved in cell migration and invasion, we specu- 
| PRMT9 induces epithelial-mesenchymal transition by activating the PI3K/Akt/GSK-3b/Snail pathway in hepatocellular carcinoma
It is well known that AKT activation plays a crucial role in inducing EMT by inhibiting GSK-3b activation and subsequently leading to Snail stabilization. In addition, it has been reported that the Akt signaling pathway is constitutively active in HCC. 20 We therefore hypothesized that PRMT9 might promote HCC metastasis through the PI3K/Akt/GSK-3b/Snail pathway. Western blot 
| DISCUSSION
In this study, we first identified a novel gene, PRMT9, whose over- The activation of Akt inhibits GSK-3b activity, subsequently suppressing the phosphorylation of Snail, inducing Snail protein stabilization and nuclear localization, which ultimately promotes EMT. 25, 26 Our data showed that the expression levels of phosphorylated Akt (active form), phosphorylated GSK-3b (inactive form) and Snail were increased or decreased when PRMT9 was overexpressed or silenced, respectively. In addition, the activation of Akt, overexpression of Snail and motility induced by PRMT9 overexpression in HCC cells were reversed by LY294002 (a PI3K inhibitor). The crucial role of Akt/GSK-3b/Snail pathway during EMT in HCC has been previously reported. 27, 28 Taken together, these findings strongly suggest that PRMT9-induced EMT in HCC is through the activation of the Akt/ GSK-3b/Snail signaling pathway. However, it remains to be determined how PRMT9 activates Akt. Many studies have shown that PTEN can negatively regulate Akt activity. 29, 30 In addition, one recent study showed that PRMT5 regulates the self-renewal capacity of primary glioblastoma neurosphere cells through modulation of the PTEN-Akt axis. 31 We speculated that PRMT9, like PRMT5, which also belongs to the type II enzymes, may regulate Akt activity via modulation of PTEN. Our western blot results showed that PRMT9
can repress PTEN expression ( Figure S4 ). Further studies are needed to elucidate how PRMT9 induces Akt activation.
Using in vitro and in vivo studies, we measured the relative expression of PRMT9, Snail and E-cadherin in HCC tissues. We found that a high expression of PRMT9 was significantly correlated with a high expression of Snail and a low expression of E-cadherin Protein arginine methylation is thought to be a reversible phenomenon, and the dysregulation of protein arginine methyltransferases has been observed in various types of cancer. 32 According to these characteristics, small-molecule inhibitors targeting protein arginine methyltransferases have been developed as anticancer drugs. 33 In this study, we showed that PTMT9 was frequently overexpressed in liver cancer, and PRMT9 overexpression significantly promoted cancer cell migration and invasion in vivo and in vitro.
Thus, targeting PRMT9 may be an effective therapeutic strategy to prevent HCC metastasis. However, for the development of effective small-molecule inhibitors targeting PRMT9, it is necessary to clarify the biological and physiological significance of other unidentified substrates by PRMT9. In addition, to better understand the biological roles of PRMT9, generating mice in which PRMT9 is overexpressed in a defined organ is essential.
In summary, this study revealed that the overexpression of PRMT9 is a strong indicator of more aggressive tumors and a poor prognosis in HCC. PRMT9 promotes HCC metastasis by inducing EMT via the PI3K/Akt/GSK-3b/Snail signaling pathway. Thus, PRMT9 may be a candidate biomarker for HCC prognosis and a potential therapeutic target.
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